These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24364190)

  • 1. [The patient is without rights if the drug company is not included in the pharmaceutical insurance].
    Eklund J
    Lakartidningen; 2013 Nov 6-12; 110(45):2005. PubMed ID: 24364190
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives. Drug formularies pose legal threat to providers.
    Moskowitz DB
    Faulkner Grays Med Health; 1995 Feb; 49(6):suppl 1-4. PubMed ID: 10139750
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmaceutical situation in the Philippines.
    Hartigan-Go K
    Aust Health Rev; 2001; 24(2):25-31. PubMed ID: 11496467
    [No Abstract]   [Full Text] [Related]  

  • 4. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 5. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 6. PBMs' rebate income threatened by lawsuits and move to generics.
    Sipkoff M
    Manag Care; 2008 Mar; 17(3):11-2. PubMed ID: 18447152
    [No Abstract]   [Full Text] [Related]  

  • 7. Senate postpones provider package, approves generic Rx bill.
    Hosp Outlook; 2002; 5(4):3, 6. PubMed ID: 12219714
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescription-drug coupons--no such thing as a free lunch.
    Ross JS; Kesselheim AS
    N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
    [No Abstract]   [Full Text] [Related]  

  • 9. Perspectives. Will we try to manage care again? This time, for drugs?
    Clemmitt M
    Med Health; 2000 Jun; 54(25):suppl 1-4. PubMed ID: 11009923
    [No Abstract]   [Full Text] [Related]  

  • 10. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs: budget busters or cost cutters in future health care?
    Egger E
    Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640
    [No Abstract]   [Full Text] [Related]  

  • 12. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Grice S
    N Z Bioeth J; 2003 Oct; 4(3):22-4. PubMed ID: 15597479
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Woolner D
    N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481
    [No Abstract]   [Full Text] [Related]  

  • 15. Forecasting the future.
    Tecnologica; 1999 Dec; ():1, 3-6, 14-5. PubMed ID: 10848110
    [No Abstract]   [Full Text] [Related]  

  • 16. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Adams J
    N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478
    [No Abstract]   [Full Text] [Related]  

  • 17. Medco becomes standalone firm.
    Thompson CA
    Am J Health Syst Pharm; 2003 Oct; 60(19):1940-1. PubMed ID: 14531236
    [No Abstract]   [Full Text] [Related]  

  • 18. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Menkes DB; Woodall AA
    N Z Bioeth J; 2003 Oct; 4(3):22, 24-5. PubMed ID: 15597480
    [No Abstract]   [Full Text] [Related]  

  • 19. Increasing generic drug use in Medicare Part D: the role of government.
    Kohl H; Shrank WH
    J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J; Ohlsson-Onerud A; Sörensen N
    Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.